食管癌的靶向及免疫检查点抑制剂治疗进展

Advances in Targeted Therapy and Immune Checkpoint Inhibitor Therapy for Esophageal Cancer

食管癌是世界上最致命的癌症之一,在中国有较高的发病率及死亡率。靶向治疗如血管内皮生长因子受体(VEGFR)抑制剂和免疫检查点抑制剂治疗如程序性细胞死亡受体1(PD-1)/程序性细胞死亡配体-1(PD-L1)抑制剂作为新型的治疗方法,已被证实在食管癌的治疗中发挥重要作用,其与放化疗的联合用药已经成为目前临床上的常规治疗手段。文章回顾了有关食管癌的现有文献数据,就食管癌靶向药物和免疫检查点抑制剂的作用机制、有效性、安全性以及最新进展进行综述。

Esophageal cancer is one of the deadliest cancers in the world and has a high incidence and mortality rate in China.Targeted therapy such as vascular endothelial growth factor receptor(VEGFR)inhibitors and immune checkpoint inhibitors such as programmed cell death protein 1(PD-1)/programmed cell death ligand-1(PD-L1)inhibitors have been shown to play an important role in the treatment of esophageal cancer as novel therapeutic approaches.Their combination with chemoradiotherapy has become a routine treatment in clinical practice nowadays.Following the recent therapeutic innovations,we have reviewed the available literature data about esophageal cancer management,with a focus on the drug mechanism,efficacy,safety,and recent advances of targeted drugs and immune checkpoint inhibitors for esophageal cancer.